We are pleased with the additional data that support the continued development of our alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO. “The data demonstrate the need for ...
Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.